1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

The overall pathological complete response in the patients suffering from non-small cell lung cancer can be increased by adding the drug nivolumab to the chemotherapy. The patients suffering from non-small cell lung cancer were enrolled ...

Read More

---

Tecentriq Injection to Overpower Ability of Cells to Outgrow in Non-Small Cell Lung Cancer

Release Date: 27 November 2020

The injection (Tecentriq) available for the treatment of small cell lung cancer is estimated to be safe as well as effective in the patients as per the result that has been posted by the group of researchers involved in the respective st...

Read More

---

Atezolizumab to be Involved in Increasing the Pathological Complete Response Rate in Triple-Negative Breast Cancer

Release Date: 27 November 2020

In the patients suffering from triple-negative breast cancer, the drug Atezolizumab is estimated to increase the overall pathological complete response by 10%. The drug used in the respective clinical research study was also able to turn...

Read More

---

CRISPR -Cas9 to Emerge as Novel Therapeutic Treatment for Myotonic Dystrophy Disease

Release Date: 27 November 2020

One of the most common type of disease that is found in young children is Myotoinc dystrophy I. The symptoms that are usually observed in the patients suffering from the disease are progressive muscle wasting and weakness and a wide vari...

Read More

---

CPMV to get Corrected by Introducing Immunotherapy Treatment in Dogs and Mouse Model

Release Date: 27 November 2020

A very important member of the Comvirus is Cowpea mosaic virus (CPMV). A novel study indicates that the virus could be used to treat different types of cancer in the patients as the clinical research study conducted in different tumors i...

Read More

---

Researchers Inclined towards Developing Next-Generation Antibodies for Cancer Treatment

Release Date: 27 November 2020

Researchers are pointing towards the potential benefits of the antibodies that can target two epitopes (bispecific antibodies) so that the cancer patients could experience dual mechanisms of action and how next-generation immunotherapy d...

Read More

---

EphA2 to Drive Resistance against BRAF Inhibitors in Melanoma Patients

Release Date: 26 November 2020

Researchers have pointed that a targeted therapy that uses BRAF-MEK inhibitors could be used as an effective treatment for the patients who are suffering from advanced melanoma. Somehow large number of patients are prone to develop resis...

Read More

---

Trio Combination of CDK4/6, MEK and RABL64 to Drive the Cancer Therapeutics Market

Release Date: 26 November 2020

Study suggests that combination of MEK inhibition and CDK4/6 is highly synergistic in killing the pancreatic neuroendocrine tumor cells. The respective research study focused on using MEK inhibitor drug called as mirdametinib and CDK4/6 ...

Read More

---

MEK and BET Inhibitors to Improve the Cancer Treatment Parameters at High Rate

Release Date: 26 November 2020

MYCN is an oncogene that is found to be regulating growth, proliferation as well as survival of the cancer cells. Research study indicated that the increased expression of the MYCN gene in the human body leads to the development of more ...

Read More

---

Nanoparticle Delivery System Boosting the Treatment Efficacy in Melanoma Patients

Release Date: 26 November 2020

A novel study indicates towards development of a nanotechnology drug delivery system in order to enhance the treatment of the patients suffering from aggressive skin cancer melanoma. The nanoparticle developed by the researchers is a bio...

Read More

---

BRAF and MEK Inhibitor Drugs to end the Resistance Developed by the Melanoma Patients

Release Date: 26 November 2020

For the overall improvement of the progression free survival as well as duration of response in the patients suffering from BRAF-mutated melanoma, researchers suggest that the addition of anti-PD-1 as well as PD-L1 to BRAF and MEK inhibi...

Read More

---

Improved Complete Response in the Patients Injected with Atezolizumab

Release Date: 26 November 2020

Combination therapy when injected in the patients suffering from stage 2 or 3 triple -negative breast cancer observed improved complete response. The combination drug that was used in the clinical research study was: neoadjuvant atezoliz...

Read More

---

CD8+ and CD4+ T Cells Neoantigens Research Work to Boost the Overall Cancer Vaccine Market

Release Date: 25 November 2020

Vaccines for a long period of time have been an efficient mechanism of treating cancer. But the overall treatment of cancer with vaccines have its own limitations. One of the disadvantages of using cancer vaccines is that besides targeti...

Read More

---

Researchers Focused towards Novel Cancer Vaccine to Stop Cancer Cells from Re-growing

Release Date: 25 November 2020

Vaccines are found to be effective in the treatment of cancer cells. The gene that is targeted by the vaccine is called as KRAS gene and it is estimated to be mutated in case of different types of cancers such as bowel cancer, pancreatic cancer and lung cancer. Accor...

Read More

---

Researchers to Classify Neoantigens as Novel Therapeutic Regimen for Cancer Patients

Release Date: 25 November 2020

Neoantigens are classified as important biomarkers for marking the cancer cells from rest of the healthy cells. It is estimated that targeting of correct neoantigens could deliver minimum side effects in the patients but the targeting of...

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |